The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy.
Joyce O'Shaughnessy
No relevant relationships to disclose
Timothy R. Wilson
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Maren K. Levin
No relevant relationships to disclose
Maria W Crockett
No relevant relationships to disclose
Jill M Spoerke
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Yuanyuan Xiao
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Carol O'Brien
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Heidi Savage
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Teiko Sumiyoshi
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Ling Fu
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Hartmut Koeppen
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Mark R. Lackner
Employment or Leadership Position - Genentech
Stock Ownership - Roche